• H C Wilson, M P Lunn, S Schey, and R A Hughes.
• Department of Clinical Neuroscience, GKT School of Medicine, Guy's Hospital, London, UK.
• J. Neurol. Neurosurg. Psychiatr. 1999 May 1; 66 (5): 575580575-80.

ObjectivesTo evaluate the response of four patients with IgM paraproteinaemic neuropathy to a novel therapy-pulsed intravenous fludarabine.BackgroundThe peripheral neuropathy associated with IgM paraproteinaemia usually runs a chronic, slowly progressive course which may eventually cause severe disability. Treatment with conventional immunosuppressive regimens has been unsatisfactory. Fludarabine is a novel purine analogue which has recently been shown to be effective in low grade lymphoid malignancies.MethodsFour patients were treated with IgM paraproteinaemic neuropathy with intravenous pulses of fludarabine. Two of the four patients had antibodies to MAG and characteristic widely spaced myelin on nerve biopsy and a third had characteristic widely spaced myelin only. The fourth had an endoneurial lymphocytic infiltrate on nerve biopsy and a diagnosis of Waldenström's macroglobulinaemia.ResultsIn all cases subjective and objective clinical improvement occurred associated with a significant fall in the IgM paraprotein concentration in three cases. Neurophysiological parameters improved in the three patients examined. The treatment was well tolerated. All patients developed mild, reversible lymphopenia and 50% mild generalised myelosuppression, but there were no febrile episodes.ConclusionFludarabine should be considered as a possible treatment for patients with IgM MGUS paraproteinaemic neuropathy.

19 keywords...

hide…